MedTech Innovator

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

KA Imaging Inc. is a Canadian company based in Waterloo that focuses on designing and manufacturing advanced X-ray detectors for both medical and non-medical applications. Founded in 2015, the company has developed the world's first portable dual energy subtraction X-ray detector, which enhances the sensitivity of disease identification, including conditions such as pneumonia and fractures. This innovative device, known as Reveal, has received FDA clearance and is sold globally. KA Imaging offers a range of products, including static detectors for identifying faults in infrastructure, dual-energy detectors for baggage screening, dynamic detectors for inspecting moving parts, and specialized mammography detectors. With a team of 20 full-time and 10 part-time employees, the company holds 52 global patents and 17 issued US patents, emphasizing its commitment to advancing X-ray imaging technology across various sectors.

Butterfly Medical Ltd is a medical device company based in Yokne'am, Israel, founded in 2014. The company specializes in developing an innovative implantable device designed to treat Benign Prostatic Hyperplasia (BPH), commonly known as enlarged prostate. This device offers a fast, simple, and minimally invasive alternative to conventional BPH treatments, such as medication and surgery. It can be placed in under ten minutes in an office setting, using local anesthesia and without the need for surgical incisions or tissue removal. This approach aims to provide a long-term solution with minimal side effects, eliminating the need for hospitalization or general anesthesia. Early clinical trials have shown promising results, with effective outcomes in relieving blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies at leading medical centers in Europe to validate its device's efficacy and safety.

Ortho-tag specializes in developing innovative technologies that facilitate wireless communication between digital health applications and implanted medical devices. Their in-vivo platform enables real-time data exchange and in-body communication through a proprietary method known as transcutaneous volume conduction. This technology enhances the functionality of smart medical implants by allowing for efficient powering, data storage, and nano diagnostic capabilities. By bridging the gap between digital health technologies and the human body, Ortho-tag aims to improve the integration and performance of medical devices, thereby enhancing patient care and monitoring.

Nanobiofab, founded in 2015 and based in Frederick, Maryland, specializes in the development of wearable, smart healthcare and medical devices utilizing nanotechnology for both humans and pets. The company is known for its product, iNose, which enables users to detect, track, and monitor their body's skin vapor-print. This device wirelessly connects to mobile phones to help individuals assess their fat burning rate and evaluate the effectiveness of their exercise routines. Additionally, it provides insights into the effects of dietary choices over time and tracks metabolic rates. Beyond consumer products, Nanobiofab also offers technology and services aimed at accelerating nanomaterial research and development, including nanoprinting solutions and artificial intelligence sensors for telemedicine and personalized healthcare applications.

Dopl Technologies, co-founded by an ex-Microsoft engineer and two Harvard-trained experts, focuses on enhancing healthcare access for underserved populations, particularly in rural areas where healthcare resources are limited. The company has developed a telerobotic ultrasound system that allows specialists to conduct diagnostic ultrasound procedures remotely, addressing the issue of specialists being predominantly located in urban centers. This innovative platform aims to improve patient access to timely care, enhance health outcomes, and provide financial benefits to hospitals by reducing costs and increasing revenue. By leveraging technology, Dopl seeks to bridge the gap in healthcare availability and ensure that quality medical services reach those who need them most.

Solenic Medical, a medical device company that develops a non-invasive treatment for infected metallic implants in the body. The company leverages the properties of alternating magnetic fields (AMF) generated from external coils to eradicate biofilm on the surface of medical implants. This non-invasive treatment addresses a major complication of various surgeries, such as knee and hip replacements, as well as in trauma-related implants such as plates and rods. Its AMF technology has the potential to completely replace the very expensive and risky two-step revision surgical procedure, which is the current standard of care for chronic infections on medical implants. Rajiv Chopra and David Greenberg founded it in College Station, Texas in 2019.

AccurKardia is a diagnostics software company specializing in ECG-led technology aimed at enhancing patient outcomes and saving lives worldwide. The company's flagship product, AccurECG™, is a cloud-based, FDA-cleared software that enables fully automated, near real-time interpretation of ECG data. AccurKardia has developed additional solutions, including AK+ Guard™, an AI-driven tool for early detection of hyperkalemia using Lead I ECG data, which has received FDA Breakthrough Device Designation. The company also created the AK-AVS™ model for aortic stenosis detection, which similarly attained Breakthrough Device Designation. AccurKardia's innovative platform combines proprietary artificial intelligence with traditional techniques to deliver clinical-grade ECG analytics, assisting cardiac monitoring companies in analyzing ECGs from various devices. The company has participated in notable accelerator programs, including the 2024 Cohort of MedTech Innovator and the American Heart Association’s Heart and Brain Health Accelerator track, further establishing its commitment to advancing cardiovascular health technology.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

Salvia BioElectronics B.V., founded in 2017 and headquartered in Eindhoven, the Netherlands, focuses on developing bioelectronic therapies for individuals with chronic neurological conditions, particularly chronic migraines. Drawing its name from the Latin word for "to stay healthy," Salvia is committed to providing drug-free, effective, and side-effect-free solutions. The company leverages a team of experienced professionals, including entrepreneurs, engineers, and scientists, who have extensive backgrounds in the medical device industry. Salvia aims to make its innovative bioelectronic solutions widely accessible, addressing the needs of patients seeking alternative treatments for their conditions.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

VinBrain is an artificial intelligence-focused company for health care. They artificial intelligence into medicine and medical image diagnostic. They provide DrAidTM Teleradiology, a remote medical imaging solution, connecting resources and expertise between hospitals to provide patients with quality diagnostic imaging services, anywhere, anytime.

HealthTech Connex Inc. is a brain technology company situated in the Health and Technology District, dedicated to advancing innovations in translational neuroscience aimed at enhancing health outcomes, particularly in neurological performance. The company focuses on brain vitality and develops technology that assesses cognitive brain health across multiple conditions, including brain injuries and neurological diseases. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex enables mental health professionals to identify cognitive impairments early, thereby improving care in both clinical and community settings worldwide.

Flow Medical specializes in the development of advanced multi-function catheters aimed at diagnosing and treating venous thromboembolic conditions, including pulmonary embolism. Their innovative platform enhances clot visualization and allows for the direct delivery of clot-dissolving medication to the blockage. Additionally, it enables real-time monitoring of treatment progress, empowering clinicians to tailor therapies to individual patient needs effectively. This approach positions Flow Medical as a key player in improving patient outcomes in the management of thromboembolic illnesses.

Progressive Neuro, Inc is a Silicon Prairie Center incubated medical device company dedicated to the development of Progressive Stroke Solutions. Progressive Neuro, Inc is focused on developing a unique portfolio of ischemic stroke devices that provide physicians with treatment options beyond aspiration and traditional thrombectomy.

FibriCheck is a medically certified mobile application designed for the screening and monitoring of irregular heart rhythms, particularly atrial fibrillation. As a software-only solution, it allows users to measure their cardiac rhythm simply by placing their finger on their smartphone camera, making it accessible anytime and anywhere. The application automatically shares gathered information with medical professionals, facilitating quicker diagnoses and enabling tailored treatment plans. Additionally, FibriCheck employs an artificial intelligence platform that is device-agnostic, leveraging everyday smartphones and wearables to accurately detect and monitor heart rhythm issues. This innovative approach aims to enhance cardiovascular care by providing users with effective tools to manage their heart health, ultimately improving efficiency and reducing costs associated with cardiovascular treatments.

SanaHeal is a company focused on developing innovative bioadhesive biomaterials, including tapes, pastes, and powders, designed to bind tissues or organs. Its bioadhesive tapes serve as an alternative to traditional sutures, promoting healing while reducing complications following surgery. This technology aims to transform the treatment of wounds and bleeding, enhancing patient outcomes. Additionally, SanaHeal's platform offers mechanical integration solutions that assist in the care of patients with multiple traumatic injuries, ensuring they receive the necessary intensive care.

X-BOLT Orthopaedics developed a novel expanding bolt device, with associated implants and instrumentation systems, for internal bone fixation in osteoporotic hip fractures. X-BOLT hip plating and nailing systems allow surgeons choice to treat all morphologies of proximal femoral fractures.

Aurie is a medical device company based in New York, established in 2018. It focuses on developing a reusable urinary catheterization system aimed at improving the quality of life for individuals with disabilities. By providing a convenient, discreet, and hygienic catheterization option, Aurie seeks to reduce the risk of infections and enhance users' confidence and control over their healthcare needs. The company's innovative approach empowers users to manage their condition more effectively, enabling them to lead active and fulfilling lives.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

iCE Neurosystems develops a neuromonitoring platform that focuses on providing early warnings and guiding treatment for patients with brain injuries. By integrating innovative devices, advanced software, and big-data methodologies, the company offers healthcare professionals real-time insights into brain health. This approach allows doctors and nurses to diagnose and prevent brain injuries in critically ill patients, enhancing their ability to deliver timely and effective care.

Craif Inc., previously known as Icaria Inc., is a Tokyo-based company founded in 2018 that specializes in developing innovative devices for early cancer detection through urine tests. The company's flagship product is a MicroRNA device that serves as a biomarker for identifying early-stage cancers. Craif aims to revolutionize cancer diagnosis by providing a method that is painless, accurate, and suitable for regular screening, addressing the critical need for early detection in order to significantly improve survival rates. Traditional cancer diagnostic methods often involve discomfort and lack the precision required for early-stage identification, which can lead to late-stage diagnoses when treatment options are limited. Craif's technology leverages exosome-based liquid biopsy tests that analyze ribonucleic acid, allowing for high sensitivity and specificity in distinguishing cancerous from non-cancerous samples.

NeuSpera Medical Inc. specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy, focusing on treating chronic illnesses through minimally invasive solutions. The company utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to direct energy to the implants. This innovative approach allows for external powering of the devices, facilitating deeper and more reliable neuromodulation treatments for conditions such as Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain. Founded in 2013 and based in San Jose, California, NeuSpera Medical is committed to advancing bioelectronic medicine.

EndoVision Limited, founded in 2018 and based in Hong Kong, specializes in the development of artificial intelligence software designed for computer-aided diagnosis in endoscopy. The company's innovative technology aims to enhance the accuracy and efficiency of medical diagnoses during endoscopic procedures, providing healthcare professionals with advanced tools to improve patient outcomes.

Cyted Health specializes in developing a digital diagnostic infrastructure aimed at the early detection of diseases, particularly cancer. By leveraging artificial intelligence and innovative biomarkers, Cyted's platform enhances clinical insights and facilitates improved patient outcomes. The company's mission is to transform diagnostic methodologies, focusing on prevention rather than treatment, thereby contributing to a healthcare landscape where diseases are identified and addressed at their earliest stages.

SmartCardia’s platform combines medical wearable technology with Artificial Intelligence to provide unique insights into patient’s health. They have developed SmartNeuralNet, a world-leading machine learning technology that powers their medical wearables. Their mission is to empower the millions of patients with chronic conditions with actionable insights to improve their health.

CytoVeris is a company focused on developing optical-based technologies to assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgeries. Founded in 2018 by Alan Kersey in Farmington, Connecticut, CytoVeris aims to enhance the surgeon's ability to achieve clean margins, thereby improving patient outcomes. The company’s devices facilitate real-time assessment of tissue and generate molecular-specific information by detecting unique signatures created by cancer cells that alter cellular metabolic processes. This includes variations in lipids, proteins, and metabolites, which can be identified using their OncoMap system. By providing oncologists with critical information during surgery, CytoVeris seeks to reduce healthcare costs associated with repeat surgeries.

TYBR Health is a medical device company based in Houston, Texas, founded in 2020 by Tim Keane and Alex Smith. The company focuses on developing a sprayable hydrogel designed to protect healing tissues and minimize internal scarring, a common complication following surgical procedures. This innovative hydrogel solution is delivered through a user-friendly device, making it suitable for both open and minimally invasive surgeries. By reducing scarring by 75% in preclinical studies, TYBR's product aims to enhance recovery and improve the healing response of tissues, ultimately benefiting patients who have undergone operations that risk damaging vital internal organs.

Promedius, established in 2019, focuses on transforming the approach to aging by developing innovative solutions for the early detection and management of musculoskeletal and metabolic diseases, particularly osteoporosis. The company aims to improve the quality of life and extend healthy lifespans through advanced technology. Its flagship product, PROS® CXR:OSTEO, is a pioneering screening solution that utilizes chest X-ray images to identify individuals at risk of osteoporosis. By employing artificial intelligence in medical imaging, Promedius provides medical professionals with efficient tools to prevent severe fractures among the elderly population, thereby contributing to better health outcomes and enhancing patient care.

Niramai Health Analytix Private Limited is a Bengaluru-based company founded in 2016 that specializes in cancer screening solutions. Its primary product, Thermalytix, is a software that utilizes machine intelligence to analyze thermography images, enabling early detection of breast cancer. This innovative approach allows for the identification of tumors significantly smaller than those detectable by traditional methods, making it a critical tool for improving survival rates. Niramai’s offerings include a compact screening device for specialty hospitals, a handheld device for independent medical practitioners with real-time cloud-based diagnostics, and a portable solution suitable for large-scale screenings. The technology is designed to be cost-effective, non-invasive, painless, and free of radiation, allowing women across all age groups to undergo frequent screenings with minimal human supervision and side effects.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at improving pelvic health. The company has developed a micro-implant that provides precision treatment for various pelvic health conditions by modulating distal target nerves locally. This technology specifically stimulates only the target nerves, allowing for less invasive and safer therapeutic options. It addresses a range of issues, including incontinence, sexual dysfunction, and chronic pain, offering patients more effective solutions for managing their health concerns.

Neurovalens Limited specializes in the development of non-invasive neurostimulation medical devices aimed at addressing global health challenges such as obesity. Founded in 2013 and headquartered in Ballymena, United Kingdom, the company offers products like Stimu Slim and Modius, which are electronic headsets designed to influence brain activity and support weight management. Neurovalens employs advanced technologies to activate specific brain regions, enabling adjustments in autonomic function and neuro-metabolic processes. The company has received funding from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme to support its research and development initiatives, enhancing its competitiveness in the field of neuroscience and bioscience.

StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor.

IFPx is a company focused on developing innovative patient monitoring technology aimed at improving the management of chronic illnesses, specifically heart failure. Its platform features advanced sensors that measure interstitial fluid pressure, allowing healthcare professionals to directly analyze fluid buildup in patients. This technology aims to enhance the monitoring and treatment of heart conditions, ultimately transforming patient care and outcomes in this critical area of healthcare.

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

AMI Corp specializes in medical consulting and the development of medical devices, focusing on telehealth solutions. The company offers a range of telemedicine services, which include a unique stethoscope system designed for remote auscultation. This innovative technology allows for the transmission of heart sounds as both audible and visual data, facilitating better access to medical care for patients through telehealth initiatives. AMI Corp aims to enhance the delivery of healthcare services by leveraging advanced communication methods in the medical field.

Mirai Medical is a medical device company focused on developing innovative technologies for cancer therapy. Its unique intellectual property allows for the painless delivery of electroporation energy through endoscopic procedures, significantly improving the treatment of cancer. This technology enables endoscopists to perform pulse field ablation safely and efficiently, ultimately aiming to enhance patient outcomes and experiences in cancer treatment.

Happitech is a pioneering company that offers a CE Certified heart rate software development kit (SDK) for Android and iOS, facilitating remote patient management through mobile applications. By integrating Happitech's algorithms, users can monitor vital signs, including heart rate and heart rate variability, utilizing only a smartphone camera. The technology is backed by clinical evidence and powered by AI, making it suitable for various applications such as cardiovascular screening, stroke prevention, and telehealth services. Happitech's solutions are designed to enhance care management, support health practitioners, and empower patients globally. The company has received multiple accolades, including recognition as one of the top Dutch COVID-19 healthcare companies and awards for its innovative contributions to digital health.

SafeGuard Surgical provides much-needed products that will ensure safer surgery for better patient outcomes while lowering costs, preventing additional surgical interventions, and reducing patient length of stay, but most importantly, preventing mortality and morbidity, which is an all-too-common risk of surgery.

Adcura, Inc. is a medical device company specializing in minimally invasive implant products aimed at enhancing the quality of life for patients with spine-related conditions. The company develops a range of innovative products, including retractors, disposable accessories, and adjustable lumbar fusion devices, which are designed to address existing surgical inefficiencies. By focusing on precision technologies and surgical techniques, Adcura enables medical practitioners to improve surgical outcomes while reducing post-operative complications for patients.

VeinWay is a medical device company focused on developing innovative solutions for chronic venous occlusions caused by blockages or disease. The firm has created a specialized catheter designed to assist physicians in recanalizing obstructed veins, facilitating the restoration of blood flow to the heart. This platform provides a dedicated tool that enables medical professionals to navigate complex blockages that were previously deemed uncrossable, thereby improving the efficiency and safety of venous treatments. By addressing the challenges associated with chronic venous disease, VeinWay aims to transform the approach to treating these conditions.

Houston-based medical device startup Prana Thoracic, Inc. is dedicated to developing solutions for early intervention in lung cancer. We are an experienced team of surgeons, engineers and entrepreneurs on a mission to tackle lung cancer; the #1 cancer killer in the US. The paradigm of screening, detection, and early intervention that has been deployed in other major cancers has so far eluded lung cancer. As a result, only 16% of lung cancers are found at an early stage and the current 5-year survival rate is < 20%. Recent changes to lung cancer screening guidelines have illuminated a path to improving outcomes in lung cancer. However, these advances rely on excising suspicious nodules and providing sufficient tissue for definitive diagnosis. We believe this is the missing piece of the puzzle, and physicians need a new generation of surgical oncology tools for lung cancer. Prana Thoracic plans to revolutionize the early diagnosis and treatment of lung cancer by making it easier and less invasive to deal with the rapidly growing number of early suspicious lung nodules; ensuring that we do not miss the window of opportunity to intervene early.

Xtremedy Medical is a medical technology based at NUI Galway that manufactures surgical devices to treat bone and deep tissue infections by sending electrical signals through wounds, both on the surface and below, to eliminate any residual infection.

StrokeDx develops rapid and portable devices to transform how strokes are diagnosed. The company's full-time software engineering team works on novel algorithms using machine learning and AI approaches to fuel the diagnostic accuracy and imaging capabilities of the StrokeDx sensor.

CerebraAI is a digital diagnostic company focused on improving stroke diagnosis through advanced artificial intelligence technology. Since its inception in 2018, the company has developed CEREBRA, an AI-powered software that enhances the efficiency of CT machines. This software enables rapid detection of acute ischemic stroke within five minutes using non-contrast computed tomography, facilitating quicker and more accurate treatment for patients. By empowering community hospitals with these innovative tools, CerebraAI aims to optimize patient outcomes in neuroradiology and address the critical time sensitivity associated with stroke care.

Perceptive Medical is a developer of medical devices focused on enhancing blood pressure management in critical care settings, specifically in intensive care units (ICUs) and operating rooms. The company's products are designed to integrate seamlessly into modern clinical workflows, providing precision in therapy and addressing inefficiencies in blood pressure management. By enabling measurable improvements in patient care, Perceptive Medical aims to support clinical providers in delivering better outcomes for patients undergoing critical treatment.

Senseye, Inc. is a company based in Los Angeles, California, focused on developing smart contact lenses that non-invasively gather data from users. Founded in 2015, the company aims to infer human emotions, thoughts, and health states to support various applications in market research, disease diagnosis, and early detection of conditions such as strokes and heart attacks. By utilizing innovative measurements of ocular physiology, Senseye quantifies cognitive abilities, health metrics, and psychological well-being, including vital signs and cognitive load. The platform is designed to enhance clinicians' ability to provide personalized care, allowing them to establish baselines and monitor patient outcomes effectively. As the technology advances, Senseye intends to place greater emphasis on emotional responses and mental health diagnostics, offering new insights into cognitive and health parameters through standard camera equipment.

Universal Brain is focused on creating individualized treatments for mental health by utilizing advanced neurofeedback therapy methods. The company engages in research and development of algorithms that integrate data from electroencephalograms (EEG) and magnetic resonance imaging (MRI) through deep learning techniques. This approach allows for the design and manufacturing of portable electroencephalograph headsets, enhancing the capabilities of mental health professionals in diagnosing and treating psychiatric conditions. By analyzing brain data, Universal Brain aims to provide valuable insights that improve the effectiveness of psychiatric care.

Endocision is focused on creating innovative minimally-invasive medical devices aimed at enhancing the diagnosis and treatment of lung diseases. The company specializes in technologies compatible with bronchoscopy and robotic bronchoscopy, offering solutions that include a cryo-biopsy platform. These advancements enable healthcare professionals to effectively diagnose and manage conditions such as interstitial lung disease and lung cancer. By prioritizing safety and efficacy, Endocision seeks to improve patient outcomes in the field of pulmonary medicine.

DasiSimulations is a company that specializes in providing innovative simulations aimed at enhancing pre-operative preparation for patients with heart disease, particularly those suffering from Structural Heart Disease. Founded in 2019 by Teri Anderson-Sirset and Dr. Dasi, and headquartered in Dublin, Ohio, DasiSimulations focuses on improving patient outcomes and reducing healthcare costs through advanced individualized computational predictive modeling. Utilizing artificial intelligence and proprietary algorithms, the company's technology platform empowers medical professionals to make more informed decisions during transcatheter aortic valve replacement procedures.

InterShunt designs and develops a catheter-based minimally-invasive procedure to provide relief for millions suffering from heart failure. It believes that left atrial decompression holds the key to reducing symptoms for those who suffer. It also believes that they can do this using a simple catheter procedure. Most importantly, they believe they can do this without the use of an implant. It was founded in 2015 and is headquartered in St Louis, Missouri.

Total Flow Medical is a medical device startup focused on enhancing the quality of life for patients undergoing cardiac surgery and life support. The company is developing innovative medical devices aimed at preventing injuries in patients who require extracorporeal circulation. Its initial product is a user-friendly cannula designed for minimally invasive cardiopulmonary bypass surgery, which helps reduce the risks of injury and death associated with traditional invasive procedures.

Sonavi Labs, Inc. is a Baltimore-based company that specializes in the development of medical devices and artificial intelligence-based software aimed at respiratory monitoring and diagnostic support. Founded in 2017, the company focuses on creating innovative products that analyze body sounds to assist in the diagnosis of respiratory diseases. By leveraging advanced technology, Sonavi Labs enables healthcare providers to detect, monitor, and potentially predict respiratory conditions by identifying abnormalities in the sounds produced by the body. This approach enhances the capabilities of medical professionals and aims to improve the patient experience in managing respiratory health.

4th Dimension EMR develops electronic health record (EHR) software aimed at assisting healthcare practitioners in managing patient information and documentation. The company offers a cloud-based platform that enhances practice management by streamlining scheduling and ensuring that medical records are accessible anytime and anywhere. This software is designed to improve workflow efficiency for medical practices, allowing practitioners to focus more on patient care while effectively maintaining comprehensive records.

Sparta Biomedical develops cartilage-like implants for the knee. They specialise in the creation of biomimetic implants that require minimally invasive therapy for chondral or osteochondral knee cartilage abnormalities, providing orthopaedic surgeons with enhancements that fundamentally restore movement for their patients.

Hypervision Surgical focuses on enhancing surgical precision, safety, and efficiency through its innovative imaging technology. The company develops an advanced non-contact and non-invasive optical imaging system that employs hyperspectral imaging to analyze tissues during surgery. By splitting light into multiple spectral bands, the system provides real-time, data-driven tissue characterization, allowing clinicians to visualize and assess tissue without the need for contrast agents. This technology aims to improve surgical outcomes while minimizing risks to patients, positioning Hypervision Surgical at the forefront of AI-powered surgical assistance.

Vitestro is a company focused on enhancing patient care through innovative autonomous blood drawing technology. It develops medical robotic devices tailored for use in hospitals and clinical laboratories. The company’s key product utilizes multi-dimensional ultrasound to detect nerves and arteries, leveraging deep learning to minimize the risk of arterial complications during blood draws. This advanced technology not only aids healthcare professionals in performing procedures with greater precision but also aims to improve overall patient health outcomes by reducing complications associated with traditional blood collection methods.

Healthcare is moving to the outpatient setting to save costs, but at home patients struggle with medication adherence and they are readmitted at alarming rates. Hospitals send 1.4 million patients home for 4-6 weeks to administer their own IV antibiotics every year. Twenty percent of patients on outpatient parenteral antimicrobial therapy (OPAT) are readmitted, each costing $80,000 on average. This is a $22.4 billion problem. Clinicians at the 12,200 home infusion providers in the US have no objective way to identify non-adherence to intervene and prevent readmissions. Rather, they call patients to detect non-adherence, which is time-consuming, inaccurate, and prone to reporting bias. They need a better tool than a phone to monitor adherence. The solution is HIVE’s patent pending CloudConnect smart catheter. CloudConnect is a reinvented IV line with a simple embedded mechanoelectrical sensor that detects when a medication source is connected. CloudConnect wirelessly sends this information to electronic medical records. HIVE’s value proposition is that clinicians can detect non-adherence in real time and make treatment decisions and prevent costly readmissions based on objective data. HIVE offers CloudConnect as an alternative to the need for clinicians to call every patient with standard IV lines.

Purgo Scientific is a medical device company focused on developing an innovative drug delivery system aimed at addressing the challenges posed by biofilm infections in orthopedic surgery. The company's technology is designed to create a sustainable, localized delivery method that targets therapeutic drugs directly to the site of infection, thereby treating and preventing biofilm-related surgical site infections that can affect orthopedic implants. This approach not only aims to eradicate infections caused by biofilms but also has potential applications in managing various health issues that benefit from precise medicine delivery, including pain management and oncology.

Knowtex provides savings in administrative work, streamlines organisational efficiency, ensures visits are billed at the appropriate level of service, and has personable conversations with patients. It helps create visit notes from medical conversations. For inquiries, an online inquiry form is available on their website.

NeuraStasis is focused on developing a non-invasive electrical neurostimulation method aimed at preventing strokes. The company has created a novel device that activates the body's natural oxygen-preserving and anti-inflammatory reflexes, which helps to preserve brain tissue during critical moments. This approach not only delays brain damage but also provides healthcare providers with additional time to intervene effectively. Ultimately, NeuraStasis seeks to empower patients to leave the hospital without disabilities following a stroke, enhancing recovery outcomes and improving quality of life.

Averto Medical is a manufacturer of medical devices focused on addressing gastrointestinal diseases. The company specializes in developing innovative solutions designed to facilitate minimally invasive colorectal tumor removal, which aims to reduce the need for multiple surgical procedures and associated complications. By providing effective medical care options for patients suffering from gastrointestinal disorders, Averto Medical seeks to improve patient outcomes and streamline treatment processes in this critical area of healthcare.

Ankr Health uses AI and telemedicine to automate side effect management in cancer and surgical clinics. Founded in 2022 and is based in San Francisco, CA.

Xcision Medical Systems, LLC is a medical technology company focused on developing advanced stereotactic radiotherapy solutions, particularly for breast cancer treatment. The company's innovative device utilizes stereotactic gamma irradiation, allowing patients to complete their radiation therapy in a single, noninvasive session, rather than over several weeks. This approach not only significantly reduces the duration of treatment but also minimizes radiation exposure to surrounding healthy tissues, including the lungs and heart. By enhancing the quality of cancer care, Xcision aims to improve patient outcomes and enable individuals to return to their daily lives more quickly and with less discomfort.

Nininger Medical is focused on developing a transcatheter tricuspid valve replacement device (TTVR) that utilizes proprietary 3D thin film technology. This innovative approach aims to provide effective treatment for heart failure, particularly in preventing structural heart issues. The company has recently received a Small Business Innovation Research grant from the National Science Foundation, underscoring its commitment to advancing medical technology in the field of cardiovascular care.

Proton Intelligence is a Canadian company, founded in 2020 and based in Vancouver, that specializes in biomarker monitoring to assist in managing chronic diseases and improving patient outcomes. The company has developed a wearable continuous potassium monitoring platform aimed at individuals with hyperkalemia, particularly those suffering from chronic kidney disease and other co-morbidities. By providing accurate and real-time potassium measurements through interstitial fluid analysis, Proton Intelligence facilitates critical health monitoring for both clinicians and patients. This technology enables informed decision-making regarding medications, diet, and treatment options, thereby enhancing the management of hyperkalemia and promoting better overall health for affected individuals.

Hertility Health is a women's health company focused on reproductive and hormonal health. It aims to reshape the landscape of reproductive healthcare by offering innovative diagnostic testing that delivers insights into reproductive health, fertility decline, and menopause. Hertility enables women to understand their symptoms through community-based home testing and evidence-based medical guidance. The company provides educational resources and access to expert advice, allowing women to visualize their biological clock and reproductive biology. This approach empowers women with actionable insights and pathways to care, all from the comfort of their homes.

CardieX is a global health technology company that focuses on hypertension, cardiovascular disease, and other vascular health disorders.

Pumpinheart is a heart failure treatment system with preserved ejection fraction (HFpEF).

Neurava is a company focused on developing non-invasive wearable diagnostic devices for patients with epilepsy, particularly those at risk of Sudden Unexpected Death in Epilepsy (SUDEP). The company's innovative device monitors critical biological signals related to epilepsy, providing timely alerts to caregivers and patients. By offering a reliable monitoring solution, Neurava aims to enhance patient autonomy and deliver peace of mind to families, facilitating timely intervention when necessary. The company's work lies at the intersection of medical device manufacturing and health diagnostics, addressing a significant need within the epilepsy patient community.

CloudMedx Inc. is a software development company that specializes in artificial intelligence solutions aimed at extracting critical clinical insights from electronic health records. Founded in 2014 and based in Palo Alto, California, the company transforms raw healthcare data into actionable insights that enhance clinical operations, documentation, and patient care. Its platform leverages population health history to improve clinical, treatment, and diagnostic outcomes, while also notifying physicians when care is necessary. CloudMedx provides patient-centric tools that facilitate engagement, risk stratification, and actionable insights, serving a range of healthcare entities including managed care organizations, accountable care organizations, physician-led organizations, emergency rooms, urgent care facilities, and lab testing sites. The company’s mission is to unify healthcare systems, enabling better collaboration among providers, payers, and patients, ultimately improving the accuracy and quality of care delivered.

ConKay Medical Systems is an early-stage medical device company advancing solutions to treat valvular regurgitation in patients with progressive heart failure.

Liquet Medical is a medical device development company that transforms the way the vascular disease is treated through localized drug delivery. The Versus Catheter will be Liquet Medical’s first technology to market.

Corveus Medical is developing a new way to prevent heart failure. It is a neuromodulation device that can uniquely reach tissues, unlocking a new field of heart failure treatment. Its goal is to develop a device that safely accesses tissue, providing consistent results.

Augment Health focuses on enhancing the management of bladder dysfunction, particularly for the 7 million patients affected by neurological diseases or injuries. The company is developing a noninvasive bladder monitor along with an AI algorithm that allows for home diagnostics, addressing the high rate of inconclusive results seen in clinical settings. By shifting bladder health monitoring out of the clinic, Augment Health's technology aims to prevent complications such as bladder muscle atrophy by notifying patients or caregivers when the catheter is full, thus promoting better bladder health management. This innovation targets a significant market valued at $12.3 billion, providing a practical solution to improve the quality of life for individuals facing bladder dysfunction.

Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "cortical remapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.

Endoluxe, Inc. specializes in the development of a portable device designed for endoscopic procedures, with a focus on creating a mobile and integrated platform that is both user-friendly and sophisticated. Founded in 2013 and located in Dunwoody, Georgia, the company offers an advanced endoscopic vision system equipped with features such as wireless display, HD camera, voice activation, and auto image stabilization. This technology is applicable across various medical fields, including Urology, Gynecology, Pulmonology, and Orthopedics. Endoluxe's system is compatible with multiple endoscopes, ensuring precise alignment for optimal visualization during surgeries. Additionally, its integrated suite of cloud-connected software features enhances the capabilities of physicians and surgeons, allowing for endoscopic procedures to be performed in diverse settings and at any time.

SymPhysis Medical's goal is to develop innovative technologies that treat a range of chronic diseases, putting the patient experience at the forefront of our design solutions to improve quality of life. About SymPhysis MedicalSymPhysis Medical's emergent technology, releaze, is a drainage technology to treat a common complication of late-stage cancers, malignant pleural effusion (MPE). MPE causes significant shortness of breath and chest pain in up to 15% of patients with cancer.

Tricog Health specializes in developing advanced cardiac diagnostic tools aimed at addressing cardiovascular conditions with precision and timeliness. Utilizing medical-grade artificial intelligence, Tricog's solutions facilitate real-time reporting and analysis of electrocardiography results, enabling healthcare providers to identify cardiac issues quickly and accurately. The company focuses on bridging gaps in cardiac care infrastructure, expertise, and efficiency, ensuring that patients receive prompt diagnoses and timely interventions. Tricog is dedicated to enhancing cardiac care accessibility by providing virtual diagnostic tools and services, thereby supporting healthcare professionals in delivering reliable and consistent patient care.

Limax Biosciences focuses on transforming tissue healing both internally and externally through its innovative products. The company has developed a degradable adhesive hydrogel that is designed for hemostasis, wound closure, and drug delivery. This hydrogel is characterized by its strong, stretchy, and flexible properties, which are derived from bio-inspired materials. By providing a reliable solution for sealing wounds and promoting healing, Limax Biosciences enables healthcare professionals to utilize its technology across various medical applications.

DermaSensor, Inc. is a Miami-based company that develops a handheld device designed to evaluate skin lesions for cancer using artificial intelligence and spectroscopy. Founded in 2009, the company's flagship product enables both physicians and consumers to conduct skin checks conveniently in clinical settings and at home. The device employs elastic scattering spectroscopy and machine learning algorithms to rapidly assess skin lesions, helping to identify potential cancerous cells. By providing an affordable and efficient tool for early detection, DermaSensor aims to improve access to skin cancer evaluations, addressing the significant number of Americans who have never undergone such checks. The technology not only facilitates immediate assessments but also alerts users when cancerous cells are detected, streamlining the process of skin cancer diagnostics.

Leadoptik is a deep-tech company focused on developing advanced miniature imaging technology designed for minimally invasive medical procedures. Its platform enhances surgical capabilities by providing high-resolution imaging and 3D navigation in real time, allowing surgeons to visualize small anatomical structures with greater clarity than existing imaging systems. This innovative approach facilitates the early detection of cancer and improves the overall effectiveness of surgical interventions, ultimately contributing to better patient outcomes.

MeaCor Inc., based in Montreal, Canada, specializes in the development of innovative transcatheter devices designed to address heart disease, particularly valvular conditions. The company manufactures a catheter-based medical device aimed at repairing the mitral and tricuspid valves, utilizing an anchoring catheter system to facilitate these procedures. This technology focuses on transcatheter interventions that minimize the risks and trauma typically associated with conventional surgical methods. By doing so, MeaCor enables effective treatment for patients who are not candidates for traditional surgery, specifically targeting those suffering from mitral valve regurgitation.

Fluid Biomed is a medical device start-up dedicated to the development of an innovative implantable dissolving stent specifically designed for the treatment of brain aneurysms. Founded by a team of neurosurgeons, the company aims to enhance patient outcomes by offering a bio-absorbable polymer-based flow-diverting stent that promotes healing and minimizes the need for invasive surgical procedures. This revolutionary device gently redirects blood flow to facilitate the healing of weakened aneurysms, enabling physicians to treat patients efficiently and effectively while reducing the risk of complications such as stroke.

Epineuron is a bioelectronic medicine company bringing a new standard of care for peripheral nerve repair and regeneration. The company is developing a suite of surgical solutions for repairing and treating peripheral nerve injuries with the mission of becoming the world leader in bioelectronic nerve care, starting with its neuroregenerative therapy.

Anumana develops advanced AI algorithms that analyze electrocardiogram (ECG) data to facilitate early diagnosis of cardiovascular conditions. The company focuses on enhancing cardiac care through innovative technology, providing healthcare professionals with tools to identify potential heart issues more effectively. Anumana's platform supports not only diagnostics but also aims to improve patient outcomes across the entire spectrum of cardiovascular care, including perioperative and acute settings. By employing machine learning techniques, Anumana seeks to refine screening processes, enabling clinicians to detect heart diseases and intervene promptly. This approach enhances healthcare delivery and promotes better management of cardiovascular health.

LiveMetric is a medical device company focused on developing non-invasive sensing and deep data analytics solutions aimed at transforming the management of hypertension and cardiovascular diseases. The company has created a wearable, cuff-free device for blood pressure monitoring, which has received FDA clearance and is validated for accuracy against traditional arterial line measurements. This device offers continuous monitoring of vital signs, enabling healthcare providers to deliver AI-augmented care and treatment management. LiveMetric aims to empower patients, payors, and healthcare professionals with accurate, personalized data, facilitating better decision-making and improving the overall quality of care for individuals suffering from chronic cardiovascular conditions. By providing detailed daily activity mapping and real-time feedback, the company seeks to enhance the lives of millions worldwide affected by these health issues.

Neurovalens Limited specializes in the development of non-invasive neurostimulation medical devices aimed at addressing global health challenges such as obesity. Founded in 2013 and headquartered in Ballymena, United Kingdom, the company offers products like Stimu Slim and Modius, which are electronic headsets designed to influence brain activity and support weight management. Neurovalens employs advanced technologies to activate specific brain regions, enabling adjustments in autonomic function and neuro-metabolic processes. The company has received funding from Invest NI as part of the European Union’s Investment for Growth and Jobs Programme to support its research and development initiatives, enhancing its competitiveness in the field of neuroscience and bioscience.

Digma Medical is a clinical stage medical device company revolutionizing the treatment of Type-2 Diabetes and other metabolic syndrome disease such as NASH. Founded in 2013 and backed by leading venture capital firms, Digma is dedicated to the development of the DiaGone™ to treat insulin resistance - the underlying mechanism of the disease. The DiaGone™ is an endoscopic, disposable device, that uses state of the art laser technology to treat the duodenum without an implant. The Duodenal Glycemic Control™ procedure is a one-time 30 minute GI procedure, in which the gastroenterologist uses the DiaGone™ to treat the duodenum for restoring the natural ability of the body to control glucose levels, which may provide long term remission from Type-2 Diabetes, NASH, and other metabolic syndrome related disease.

Gravitas Medical, founded in 2015 and based in San Francisco, California, focuses on developing a personalized automated nutrition management system tailored for hospital settings. The company's innovative nasogastric feeding system evaluates patient readiness for feeding and enhances the delivery of nutrition. By optimizing these processes, Gravitas Medical aims to improve patient health outcomes, decrease overall healthcare costs, and alleviate the workload of nursing staff.

Endiatx, Inc. is a medical device manufacturing company based in Redwood City, California, specializing in innovative pill-sized robots designed for remote diagnostics and treatment within the gastrointestinal (GI) tract. Founded in 2019, the company has developed the Endiatx Pill Surgeon and the Endiatx Pill Robot, both of which feature advanced propulsion systems that allow them to navigate the entire length of the GI tract in about 30 minutes. These devices provide real-time video control, enabling physicians to perform sedation-free endoscopies in challenging areas, thus enhancing diagnostic capabilities and patient comfort.

Endoron Medical specializes in the development of medical devices aimed at improving the treatment of abdominal aortic aneurysms. The company focuses on creating an endovascular suture device that enhances the effectiveness of endovascular aneurysm repair procedures. By designing long-lasting sealing equipment for endografts, Endoron Medical provides healthcare professionals with advanced technology to treat patients more effectively. This innovation is intended to improve patient outcomes and streamline surgical processes in the management of abdominal aortic aneurysms.

New View Surgical, Inc. is a medical device company based in Boston, Massachusetts, that specializes in the development and commercialization of the VisionPort technology. This innovative system consolidates four essential surgical devices—a laparoscope, camera, light source, and access port—into a single, easy-to-use, and disposable unit. The VisionPort system aims to enhance minimally invasive surgical procedures by providing surgeons with complete control over visualization and instrumentation. Founded in 2009, the company is led by a team of experienced professionals dedicated to addressing unmet needs in the medical field, offering potential clinical and economic advantages for operating rooms worldwide.

MindMics is an innovative wearable technology company focused on health monitoring through sound-based platforms integrated into earbuds and hearing aids. By capturing clinically meaningful biometrics in real-time, such as circadian rhythms, breathing rates, body temperature, and heartbeats, MindMics aims to enhance mental performance and overall well-being. The technology allows users to gain insights into their health, facilitating improved focus, satisfaction, and mindfulness. Through this approach, MindMics seeks to provide users with tailored products and experiences that promote mental peace and enhance daily living.

EvoEndo specializes in developing innovative systems that facilitate unsedated endoscopic procedures for both pediatric and adult patients. The company combines sterile, single-use, multi-specialty flexible endoscopes with a virtual reality-based distraction method, allowing patients to undergo routine endoscopies without the need for general anesthesia or sedation. This approach not only reduces the complexity and cost of the procedures but also alleviates patient and provider apprehension. EvoEndo's comprehensive software integration platform further enhances the effectiveness of its technology, streamlining the endoscopic process and promoting a more comfortable experience for patients.

Aqua Medical, Inc. is focused on developing innovative, vapor-based, endoscopic ablation technology aimed at treating gastrointestinal diseases and preventing gastrointestinal cancers. Founded in 2016 and based in Santa Ana, California, the company utilizes high-temperature water vapor generated by a radiofrequency generator. This vapor is delivered endoscopically through proprietary catheters, allowing for a minimally invasive approach to treat various conditions within the gastrointestinal tract, including pancreatic cysts and esophageal issues. Aqua Medical's platform technology offers a convenient and effective alternative to traditional surgical methods, enhancing treatment options for medical practitioners and their patients.

PopCheck Technologies is an early-stage firm that specializes in remote postoperative monitoring technologies.

Discure Technologies is developing a minimally invasive, implantable bioelectronic device designed to treat and reverse degenerative disc disease (DDD), healing the disc, reducing pain, and restoring function to patients.

Healthcare X.0 is an online healthcare platform that provides its clients with digitization solutions. The platform provides its clients with health, vascular, patient, onco, nephro, cardio, wound, tele, patient, and diabetic assist database solutions. Healthcare X.0 was launched in 2013 by and is based in Niedersachsen.

PyrAmes has developed a paper thin, flexible, ultra low power device for non-invasive monitoring of blood pressure